U.S. Condemns China's Dominance in Global Shipbuilding and Maritime Sectors 
UK Markets Face Rising Volatility as Hedge Funds Target Pound and Gilts 
Wall Street Rebounds as Investors Eye Tariff Uncertainty, Jobs Report 
Netflix’s Bid for Warner Bros Discovery Aims to Cut Streaming Costs and Reshape the Industry 
Amazon Debuts “Amazon Now” for 30-Minute Ultrafast Grocery Delivery 
Ferrari Group to Launch IPO in Amsterdam, Targets Over $1 Billion Valuation 
Tempus AI Stock Soars 18% After Pelosi's Investment Disclosure 
UPS MD-11 Crash Prompts Families to Prepare Wrongful Death Lawsuit 
Reliance Industries Surges on Strong Quarterly Profit, Retail Recovery 
Trump Administration to Secure Equity Stake in Pat Gelsinger’s XLight Startup 
SoftBank Eyes Up to $25B OpenAI Investment Amid AI Boom 
Samsung Launches Galaxy Z TriFold to Elevate Its Position in the Foldable Smartphone Market 
Microchip Technology Boosts Q3 Outlook on Strong Bookings Momentum 
EU Prepares Antitrust Probe Into Meta’s AI Integration on WhatsApp 
Momenta Quietly Moves Toward Hong Kong IPO Amid Rising China-U.S. Tensions 
Rio Tinto Raises 2025 Copper Output Outlook as Oyu Tolgoi Expansion Accelerates 
Elliott Investment Management Takes Significant Stake in BP to Push for Value Growth 
Samsung Biologics would invest 1.74 trillion in building a massive fourth plant in Songdo, Incheon, that would employ 1,800 new employees by 2023 and produce 256,000 liters of drug substances in a single generation.
According to CEO Kim Tae-han, the construction will increase its output at its Songdo complex 1 to 620,000 liters, accounting for 30 percent of the world’s contract manufacturing market.
Samsung Biologics currently has a combined 364,000-liter capacity at its three existing plants, with one of those producing 180,000 liters and touted as having the world’s largest single-plant capacity.
Construction of the fourth plant will take 36 months and poised to create 27,000 jobs and bring in 5.6 trillion won in economic benefits.
Plant 4 will be a hybrid that has both stainless steel and single-use disposable bioreactors.
With speed being of critical significance in the biologics market, the new plant will be a game-changer.
It would provide a one-stop service comprising of cell line development and the manufacturing of clinical samples, active pharmaceutical ingredients, drug substances, and fill-and-finish drug products.
The one-stop service would dramatically reduce the time spent on commercializing a drug.
